it is not just covid-related tharps they are bullish on jeff meacham is senior analyst at bank of americar having me. happy new year. >> to you as well. what do you think is still to come for pfizer when it feels like so much should be in their recent past? >> good question i think the oral covid pill is going to have a robust launch provided they can scale it up. there is a lot of other goings on in pfizer's pipeline. we evaluated their cash flow they can generate more than $100 billion in cash in the next four years. m & a could be a big part of the story this year and next >> could you describe a little bit what we see maybe anticipate on that front? >> you know, what they have said is they want to go after companies in similar therapeutic areas. so probably not going to buy technologies or things like that so i would say larger scale deals that -- you know, not mega pharma deals but let's call it ms.-sized biotechs that could solve the l.o.e. problem that they have starting in 2025, 2026. >> what's loe? >> patent expirations. >> got it. why thung they are more well positioned as moder